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Abstract 
 
Problem: Necrotizing Enerocolitis (NEC) is one of the leading causes of morbidity and 
mortality in neonatal intensive care units (NICU), affecting 7% to 14% of premature neonates 
weighing less than 1500g (Lin et al., 2008). Healthcare costs for the treatment of NEC account 
for roughly 20% of the 5 billion dollars spent on infants in the NICU annually (Gephart, 
McGrath, Effken & Halpern, 2012). Nutritional supplements, such as probiotics, may be used 
prophylactically to prevent NEC in this high-risk population.  
Objective: A literature review was performed to examine which strains of probiotics show the 
most potential in reducing the incidence of necrotizing enterocolitis.  
Method: A literature review was performed using CINAHL, Science Citation Index, Science 
Direct, Medline, Academic One file, PsychINFO, and PUBMED databases. Key words included 
enterocolitis, Necrotizing*/PC OR NEC* AND probiotics*. After applying exclusion criteria, 9 
articles remained for this review.  
Results: A variety of probiotic strains used to reduce the incidence of NEC were identified, 
along with inconsistent times of initiation, number of colony forming units and length of 
treatment. The most commonly studied probiotic strains include Lactobacillus species, 
Bifidobacterium species, and Saccharomyces species. After detailed analysis, it appears that a 
combination of Bifidobacterium species and Lactobacillus species reduce the incidence of NEC 
from an 8% (Fernández-Carrocera et. al, 2013) reduction up to 100% reduction in the incidence 
of NEC (Braga, Pontes da Silva, Cabral de Lira, & Lima,  2011).  These two species, when 
combined, were more successful when compared to Saccharomyces species or Lactobacillus 
species alone.  
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Conclusion: Although there is positive support for the proactive use of probiotics for the 
reduction of the incidence of NEC in premature neonates, the inconsistencies between studies are 
a barrier for determination of a specific treatment recommendation. Although the combination of 
Bifidobacterium species and Lactobacillus species has been shown to have an impact on the 
reduction of NEC incidence, the research inconsistencies provide a barrier to generalizations for 
treatment.  Additional research that focus on Bifidobactrium species in combination with 
Lactobacillus species is needed. Furthermore, the use of probiotics as a preventative treatment 
for NEC has not been thoroughly researched in extremely premature infant populations (<28 
weeks gestation). Therefore, although the results are promising, further research is needed before 
this can be determined as a safe preventative method. The current questions remaining include: 
when prophylactic treatment should be initiated, how long prophylactic treatment should last, the 
number of colony forming units to be administered, and what is the long-term impact of 
probiotic administration on the normal gut flora, if any.  
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 1 
Introduction 
 
Necrotizing Enerocolitis (NEC) is one of the leading causes of morbidity and mortality in 
neonatal intensive care units (NICU), effecting 7% to 14% of premature neonates weighing less 
than 1500g (Lin et al., 2008). A neonate is classified as premature when born before the 37th 
week of gestation. Of the neonates suffering from NEC, it is estimated that roughly 30% will not 
survive and  although technological advances have improved care for increasingly premature 
neonates, the incidence of NEC has not decreased in over 20 years (Gephart, et al., 2012; Neu, 
Mshvildadze, &Mai, 2008). Treatment of NEC has a significant financial impact accounting for 
roughly 20% of the 5 billion per year cost for all NICU treatment costs in the United States 
(Gephart et al., 2012). The immediate treatment cost for a single neonate diagnosed with NEC 
ranges between $73,000 and $182,000 depending on surgical needs. In addition to financial 
hardship, neonates with NEC typically stay in the NICU 22 to 60 days longer than the average 
NICU patient (Gephart et al., 2012). This prolonged stay in the NICU also generates an 
emotional hardship on the family as well as disrupting early infant bonding.  
 Recent studies involving the use of probiotics have shown promising results in terms of 
reducing the incidence of NEC (Thompsom & Bizzarro, 2008). The World Health Organization 
defines probiotics as “live microorganisms which when administered in adequate amounts confer 
a health benefit on the host” (World Health Organization [WHO], 2001). Further studies need to 
be conducted to determine the most effective treatment plan including the optimal time of 
initiation, length of time treatment is implemented, as well as the combination of probiotics used 
for treatment.    
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Background 
 
Necrotizing Enterocolitis  
 
 Necrotizing Enterocolitis (NEC) is a multifactorial gastrointestinal (GI) disease in which 
areas of a newborn’s bowel become necrotic (the tissue dies). In 2011, the National Healthcare 
Safety Network (NHSN) updated the clinical and surgical criteria for the diagnosis of NEC. 
These updated criteria stated that for an infant to be diagnosed with NEC based on clinical and 
radiographic criteria, they must present with bilious aspirate, vomiting, abdominal distension, or 
occult blood in stool, plus one or more of the following radiographic signs: pneumatosis 
intestinalis, which is gas in the bowel wall, portal venous gas, or pneumoperitoneum (National 
Healthcare Safety Network [NHSN], 2011). Furthermore, the surgical criteria for NEC are that 
the infant must have more than two centimeters of necrotic bowel or surgical evidence of 
pneumatosis intestinalis, with or without intestinal perforation (NHSN, 2011).  
Prematurity  
 
NEC is almost exclusively seen in preterm neonates (Sari, et al., 2011). An infant born 
before the 37th week of gestation is considered premature. The presentation rate of necrotizing 
enterocolitis is indirectly proportionate to the age of a neonate (Gephart et al., 2012). That is, the 
earlier a neonate is born, the longer it will take for NEC to present. For example, the average 
onset of NEC in a neonate born at the 28th week of gestation is 40 days, whereas the average 
onset for a neonate born at 36 weeks is 5 days (Mayer, 2011).  
Due to this near exclusive presentation, gut prematurity is believed to be a primary 
inciting factor of the disease. The gastrointestinal tract is developed from all three of the 
embryonic germ layers, the endoderm, mesoderm and ectoderm (Mayer, 2011). Development of 
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the fetal gut is broken down into four distinct phases: formation of the endoderm, morphogenesis 
and patterning of the gut tube, and organ morphogenesis and terminal differentiation (Mayer, 
2011). While this maturation predominately takes place during the first trimester, the muscular 
maturity and hormonal maturity that control motility does not begin until the second trimester 
and continues until term (Braga et al., 2011). More significantly even, the “waves” of peristalsis 
needed for elimination are not seen in their entirety until a gestational age of 33 to 34 weeks 
(Braga et al, 2011). Therefore, gastric emptying is severely impaired for infants less than 32 
weeks gestation. Due to the increased peristaltic waves seen at 33 weeks gestation, the majority 
of research investigating NEC excludes infants older than 32 weeks gestation (Braga et al., 
2011).  Despite this impaired gastric emptying, it is commonly suggested that enteral feeding 
commence as soon as possible once an infant is clinically stable (Ayede, 2011) This prevents a 
decrease in digestive enzymes as a result of mucosal and villous atrophy (Ayede, 2011).  
The longitudinal and transverse muscles are responsible for the peristaltic action of the 
bowels (Mayer, 2011). Peristalsis is a mechanism used by the intestines to remove digested food 
and pathologic bacteria. Therefore, premature infants with immature intestinal smooth muscle 
consequently have decreased gut motility. This decreased motility may lead to a build-up in 
pathologic bacteria.  
Bacterial Colonization  
 
Gastrointestinal microbiota is a dynamic ecosystem with approximately 500 to 1000 
differing species of bacteria that colonize the gastrointestinal tract of a healthy infant (Guaraldi, 
F. & Salvatori, G., 2012). This gut microbiota influences the growth and differentiation of gut 
epithelial cells and have a role immunologic and protective functions (Guaraldi, F. & Salvatori, 
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G., 2012) Molecular studies have shown that the guts of healthy breast-fed and formula-fed 
infants consist of 60% to 90% Bifidobactrium species with the most common strains of 
Bifidobactrium being B. bifidium, B.longum,and B. breve (Lin et al., 2008). Another primary 
physiologic bacterium are Lactobacillus species which have been shown to induce anti-
inflammatory cytokines such as interleukin 10 (Lin et al., 2008).  
Studies demonstrate that the gut microbiota of a term breast-fed infant and a term 
formula-fed infant have no significant differences (Guaraldi, F. & Salvatori, G., 2012). However, 
it has been reported that breast-fed newborns have a more uniform and stable population of 
bacteria and have two times the number of bacteria cells when compared to formula-fed 
newborns (Bezirtzoglou, Tsiotsias, & Welling, 2011). It is consequently appropriate to 
hypothesize that various strains of Bifidobacterium would have the greatest positive affect on 
reducing the incidence of NEC.  
While a neonate is in utero, the intestine is sterile, surrounded by amniotic fluid 
(Guaraldi, F. & Salvatori, G., 2012). Bacterial colonization begins at birth and is influenced by 
several external factors such as mode of delivery, vaginal, or cesarean section, the environment, 
such as equipment, air and other people, and the ingestion of colostrum(the mother’s initial milk)  
if the mother is breast feeding (Guaraldi, F. & Salvatori, G., 2012). During vaginal delivery, the 
newborn comes into direct contact with the maternal vaginal and intestinal flora via the ocular, 
nasal and oral cavities. This direct contact is absent in a cesarean section and gut bacteria is 
derived primarily from environmental factors (Guaraldi, F. & Salvatori, G., 2012). For this 
reason, vaginal delivery is associated with a greater biodiversity of healthy bacteria within the 
newborn gut (Godhia, M.L. & Patel, N., 2013).  Colostrum is rich in antibodies that give passive 
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immunity to a newborn, growth factors that mature the gut epithelial cells, which prepare the 
newborn for human milk or formula, and antimicrobial peptides (Godhia, et al., 2013). 
Conversely, premature births are associated with higher rates of cesarean sections, hindered 
ability to breastfeed, due to delayed onset of lactation (Neu, J. & Rushing, J., 2011), and the 
newborn being surrounded with equipment in the NICU (Godhia, et al., 2013). These factors 
alter the introduction of bacteria to the newborn and as a result the preterm gut is predominately 
colonized by Staphlococccus, Enterobacter, Enterococcus, and Clostridia (Thompsom & 
Bizzarro, 2008). These pathologic bacteria then compete with the natural gut flora for nutrients, 
and if uncontrolled, an overabundance of pathologic bacteria can be a precursor to 
gastrointestinal disease such as NEC.  
At birth, even in an infant born at term, the immune system has not fully matured. The 
adaptive immunity gains specificity into early childhood (Melville, J.M. & Moss, T., 2013). 
Immaturity of the immune system is even more pronounced in the preterm infant (Melville, J.M. 
& Moss, T., 2013). There is a reduced number of monocytes and neutrophils and a lower 
productions of cytokines which reduces the preterm infant’s ability to recognize and kill 
pathogens when compared to the term newborn (Melville, J.M. & Moss, T., 2013). Due to this 
reduced ability to detect and neutralize bacteria and viruses, preterm infants are typically placed 
on broad-spectrum antibiotic therapy to reduce the bacterial load their immune system faces 
(Melville, J.M. & Moss, T., 2013). These antibiotics consequently further reduce the biodiversity 
of the preterm gut bacteria. Pathologic bacteria within the gut accumulate due to both decreased 
GI motility and these immunologic deficiencies.  
 6 
Broad-spectrum antibiotics are also administered to mothers who go into premature labor 
or who have a cesarean section even prior to birth. This may also be a contributing factor that 
reduces the biodiversity of gut microbiota in preterm infants (Neu, J. & Rushing, J., 2011). 
Oxygenation 
 
A third inciting factor believed to contribute to NEC is hypoxic-ischemic injury. Any 
congenital or environmental factor that affects the oxygenation of the newborn, such as patent 
ductus arteriosus, respiratory distress, or in utero cocaine exposure, can lead to hypoperfusion. 
(Thompsom & Bizzarro, 2008).  Decreased oxygenation and subsequent decreased organ 
perfusion is a common problem in premature infants. This can be attributed to the immature lung 
formation and lack of surfactant in the premature infant’s lungs. Surfactant production begins at 
roughly 32 weeks gestation and reduces surface tension at the air-liquid junction of the alveolus 
subsequently allowing the alveoli to expand to capacity to perfuse the capillaries surrounding the 
alveoli (Nkadi, P., Merritt, T., & Pillers, D., 2009). To combat the lack of surfactant production, 
preterm infants are treated with antenatal corticosteroids and exogenous surfactant upon birth 
(Nkadi, P. et al., 2009). Without sufficient oxygen exchange between the lungs’ alveoli and the 
blood there is hypo-oxygenation of organs throughout the body. During times of hypo-
oxygenation, the body shunts blood to vital organs, such as the brain and heart, and away from 
“non-vital” organs, such as the intestines (Thompsom & Bizzarro, 2008). This subsequent 
decrease in oxygen to the gut causes a hypoxic-ischemic state. If the hypo-oxygenation is 
reversed, reperfusion can cause a proinflammatory cascade leading to damaged mucosal barrier 
by tumor necrosis factor α (TNF α) and platelet activating factor (Gephart et al., 2012). 
Inflammation, which reduces cell membrane integrity, is likely to cause hyperpermeability of the 
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intestinal wall, thus creating an opportunity for bacteria to permeate the gut lining. If bacteria 
continues past the gut lining, into the peritoneal cavity, sepsis and death can occur (Gephart, et 
al. 2012). 
Diagnosis Necrotizing Enterocolitis  
 
Diagnosis of NEC is oftentimes difficult due to its nonspecific clinical manifestations in 
the early stages. Temperature instability is one of the most common early signs of NEC while 
other signs may include apnea, low oxygen saturation, lethargy, and bradycardia (Thompsom & 
Bizzarro, 2008).  As the disease progresses, there may be GI specific manifestations, such as a 
distended abdomen, feeding intolerance, and blood in the infant’s stool (Thompsom & Bizzarro, 
2008). Common diagnostic tests include an abdominal x-ray and serum analysis. According to 
Thompsom and Bizzarro (2008), radiographic signs of NEC may include dilated or fixed 
intestinal loops, air in the intestinal wall or free air in the abdomen.  Serum analysis may show 
low platelet count and/or elevated white blood cells, although nonspecific, this is an indication of 
infection (Thompsom & Bizzarro, 2008). Based upon the combination of these diagnostic tests, 
the severity of NEC can be staged using the Bell’s criteria. Stages range from IA: Suspected to 
IIIB: Advanced, severely ill, perforated bowel (Thompsom & Bizzarro, 2008).  
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Figure 1: Bell's Classification of NEC  
Stage  Classification Intestinal Signs Radiologic Signs Systemic signs 
IA Suspected NEC Decreased gastric 
emptying, 
abdominal 
distention, emesis 
Normal or 
intestinal dilation 
Temperature 
instability, 
apnea, 
bradycardia, 
lethargy 
IB Suspected NEC Bright red blood 
from rectum.  
Same as IA Same as IA 
IIA Proven NEC-mild Same as IA plus 
absent bowel 
sounds, with or 
without abdominal 
tenderness 
Intestinal dilation, 
ileus, and 
pneumatosis 
intestinalis.  
Same IA 
IIB Proven NEC- 
moderate 
Same as IIA with 
definite abdominal 
tenderness and 
with or without 
right lower 
quadrant mass 
Same as IIA plus 
portal venous gas 
with or without 
ascites 
Same as IA plus 
mild metabolic 
acidosis and 
thrombocytopenia 
IIIA Advanced NEC-
bowel intact 
Requires surgery. 
Same as IIB with 
generalized 
peritonitis, marked 
tenderness, and 
distention of 
abdomen 
Same as IIB with 
definite ascites 
Same as IIB with 
hypotension, 
bradycardia, 
apnea, respiratory 
and metabolic 
acidosis and 
neutropenia 
IIIB Advanced NEC- 
bowel perforation 
Requires Surgery. 
Same as IIIA Same as IIB with 
pneumoperitoneum 
Same as IIIA 
Adapted from Lee & Polin, 2003 
Treatment of Necrotizing Enterocolitis 
 
Treatment of NEC ranges from bowel rest for suspected NEC, the use of antibiotics along 
with bowel rest for proven but mild NEC, to surgery for advanced NEC. When NEC progresses 
into the “advanced” stages of NEC and requires surgery, it is termed “surgical NEC” and the 
long-term prognosis for the infant decreases. Long-term ramifications of surgical NEC include 
short bowel syndrome and neurodevelopment impairment (NDI) (Schulzle S.M., Desphande 
G.C., & Patole SK, 2007). Due to its costly and deadly nature, an effective preventative strategy 
needs to be further researched and implemented (Fanaroff, A. A. & Fanaroff J. M., 2013).  
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There are multiple proposed strategies for the prevention of NEC. These strategies 
include antenatal corticosteroids, which have been shown to mature the gut in a manner similar 
to the mechanism enhancing lung maturation; trophic feedings in which small volumes of enteral 
feedings are introduced in order to facilitate peristaltic action; oral antibacterials, in an effort to 
reduce the number of pathogenic bacteria; and prebiotics, used to selectively increase the 
population of commensal GI bacteria. And lastly, the use of probiotics, thought to be the most 
promising of therapies, and the focus of this literature review (Thompsom & Bizzarro, 2008).  
The Pharmacodynamics of Probiotics 
 
 The knowledge that a healthy newborn delivered at full term has a gut primarily 
consisting of Bifidobactrium species (Lin et al., 2008), while the preterm newborn has a gut 
microbiota consisting primarily of staphlococci, enterobacter, enterococci, and clostridia bacteria 
(Thompsom & Bizzarro, 2008) led researchers to hypothesis that the use of probiotic 
supplementation would decrease the incidence of NEC. Probiotics are dietary supplements that 
introduce indigenous microbes to the human GI tract and confer a health benefit to the infant 
(Janvier, Malo & Barrington, 2014). It has been recently supported in research that probiotics 
“provide benefit to preterm neonates by enhancing the IgA mucosal response, improving the 
mucosal protective barrier, increasing the production of anti-inflammatory cytokines, decreasing 
intestinal wall permeability and competitively excluding pathogenic microbes” (Thompsom & 
Bizzarro, 2008, pp. 1234). 
  The indigenous microbes in a healthy human GI tract also aid in the digestion of protein 
and carbohydrates. Therefore, the administration of probiotics to preterm neonates could 
potentially result in a decrease in the rate of NEC, increased feeding tolerance, and a reduced rate 
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of sepsis. Of the studies investigating probiotics as a prevention strategy for NEC, the most 
commonly studied species have been those that include Bifidobacteria, Lactobacillus, and 
Saccharomyces (Thompsom & Bizzarro, 2008). 
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Problem 
 
Plateau in Incidence  
 
Although technology and treatment options have expanded which has increased the ability 
to care for and sustain increasingly premature infants, for example those born less than 28 weeks 
gestation, the incidence of NEC has plateaued rather than declined. The reason for this plateau is 
that the incidence of NEC is inversely proportional to gestational age. That is, there is a greater 
number of infants who develop NEC at 32 weeks gestation than there are at 36 weeks gestations 
(Gephart, et al. 2012). Due to this sustained occurrence rate recent research has shifted from 
treatment to prevention.   
Mortality  
 
NEC is a devastating disease that is responsible for 20%-25% percent of preterm and low 
birth weight deaths each year (Deshpande, G.C. Rao, S. Patole, S., & Bulsara, M., 2010).With this 
being a disease that ranks as the second highest cause of death among NICU patients (Deshpande 
et al., 2010), it is making its way to the forefront of neonatal research. However, there still remains 
little knowledge as to the intricate details and microbiota of the disease.  
Cost of Hospitalization 
 
NEC poses a significant financial burden, accounting for 20% of all neonatal treatment at 
nearly 5 billion dollars spent each year treating the disease (Gephart et al., 2012). It is estimated 
that an infant diagnosed with NEC, will stay on average an extra 22 days longer in the hospital 
than other infants of comparable gestational age (Gephart et al., 2012). Furthermore, the cost of 
treating one infant with NEC has been reported to be as high $216,666 per survivor (Deshpande, 
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et al., 2010). Research by Johnson and colleagues (2013) indicates that medically treated NEC, 
which is stages 1 and 2 that do not require surgery, increased hospital direct costs by $13,136 
(p=0.034) and surgically treated NEC, which is Stage 3 or “advanced NEC”, increased hospital 
direct costs by $22,328 (p=0.039) when compared with infants without NEC of similar gestational 
age, birth weight and demographics (Johnson, Patel, A., Jegier, Engstrom, & Meier, 2013). Directs 
costs include all chargeable items such as electrolyte panel, room charges and medications, during 
the infant’s hospital stay (Johnson et al., 2013). These increased costs can be attributed to not only 
the increased length of hospital stay but also the additional care needs (Johnson et al., 2013). Given 
this significant financial burden the benefits of a prophylactic treatment aimed at reducing NEC, 
such as probiotics, is significant.  
Lack of Research 
 
There is a paucity of research and inconsistent methodologies amongst the current research 
concerning probiotics and their ability to reduce NEC. Specifically, there has yet to be a study 
design replicated to validate previously reported results. Without replicated studies that validate 
the benefits of a particular probiotic strain, dosage or administration protocol,  health professionals 
are reluctant to implement the use of them in standard practice or recommend the use of probiotics 
to caregivers with any guarantee.  
Cost of Probiotics 
 
Probiotics are neither drug nor device and they are unregulated which makes then unique 
in terms of medical intervention (Taylor, R. S, 2014). Annie Javier and colleagues form the Sainte 
Justine University Health Center in Canada investigated the use of probiotics to reduce the 
incidence of NEC. They reported great success with nearly a 50% reduction in NEC incidence 
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(Janvier, 2014). Janvier et al., (2014) reports using a commercially available probiotic: 
FloraBABY. The researchers reported that this probiotic cost a mere 11 cents per day. In this 
particular study, the average length of treatment was 24 days. Therefore, the cost per infant was 
only $2.51(Janvier et al., 2014).  
  
 14 
Purpose 
 
The purpose of this review is to evaluate the current research findings regarding the 
potential for probiotics to prevent NEC in premature (<37 weeks gestation) neonates admitted to 
the neonatal intensive care unit (NICU). A literature review was performed to examine the 
current evidence. Probiotic strands will be identified that either decrease, increase or produce no 
effect on the reduction of NEC, and the findings will be discussed.  
 The secondary purpose of this research is to make recommendations for current practice 
and future practice based on the findings in this study. The final purpose of this study is to make 
recommendations for future research based on the findings in this study.  
 Current studies lack consistency in their choice and combinations of probiotics. These 
methodology differences have made it difficult to determine the most beneficial probiotic 
supplement to premature neonates. Therefore, the overall purpose of this research is to identify 
the probiotic strand or combination of probiotic strands that have the highest potential for 
decreasing the incidence of NEC in premature neonates.  
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Method 
 
The focus of this comprehensive literature review will examine the effectiveness of 
probiotics in decreasing the incidence of NEC in premature neonates. Information will be 
obtained from CINAHL plus full text, Science Citation Index, Science Direct, Medline, 
Academic One file, PsychINFO, EBSCOhost databases, and PUBMED to determine research, 
which has been conducted, and the extent probiotics have shown to be effective. A scholarly 
search of these databases will be conducted using the key words enterocolitis, Necrotizing*/PC 
OR NEC* AND probiotics*. Literature criteria for this comprehensive review will consist only 
of randomized control trials (RCTs) and quasi-randomized trials, peer-reviewed articles, research 
articles, and articles written in the English Language no earlier than 2005. Population criteria for 
this literature review will consist of neonates that are premature (<37 weeks gestations). 
Neonates being fed breast milk, formula or a mixture of both will be eligible for inclusion in this 
review. Additionally, probiotic supplementation must have commenced prior to the corrected 
gestation of 40 weeks. This literature review will exclude data on neonates that have prior 
genetic anomalies, gastrointestinal malformations, and/or prior diagnosis of NEC based on Bell’s 
criteria. After applying exclusion criteria, 9 articles remained for this review.  
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Figure 2: Method 
 
 
 
 
 
 
 
 
 
 
  
  
199 articles were 
identified 
4 articles in a foreign 
language were 
eliminated
195 articles remained 
5 repeated articles 
were eliminated 190 articles remained
96 did not answer the 
question
94 articles remained
87 articles eliminated 
due to study design 
not meeting inclusion 
criteria 
9 articles remained
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Findings 
 The literature review returned over 12 strains of probiotics that have been studied to 
determine their effectiveness in preventing necrotizing enterocolitis. Staggering variances in 
methodologies between the studies created a problem when trying to identify a clinically 
significant approach to reduce the incidence of NEC. To better organize and discuss the 
numerous strains studied they have been divided into three categories that include 
Bifidobacterium species combined with Lactobacillus species, Lactobacillus species used alone, 
and Saccharomyces species. Within these three categories the research articles are compared 
based on: incidence of NEC, participant demographics, specific type and strength of probiotic 
and finally, the timing of the introduction, duration of administration and feeding regimes.  Each 
section highlights evidence that shows how a particular species of probiotics may or may not 
prevent NEC.  
Bifidobacterium Species combined with Lactobacillus Species 
 
 The literature review returned 3 research studies that met the inclusion criteria, which 
investigated the combined use of Bifidobacterium species and Lactobacillus species in terms of 
reducing the incidence of NEC.  
Incidence of NEC 
 Both Lin et al., (2008) and Braga et al., (2011) found a statistically significant reduction 
in the incidence of NEC. Lin et al., (2008) reported that only 1.8% of the infants in the study 
group developed NEC, whereas 9.2% of infants in the control group developed NEC. With a p-
value of 0.002, this was an incredibly significant decrease despite the potential center variations 
this study encountered. Likewise, Braga et al., (2011) reports similar results with 0% of 
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participants in the study group developing NEC versus 3.6% in the control group. With a p-value 
of 0.05 this is also statistically significant.  
 The only study included in this review, which investigated the combined effects of 
Bifidobacterium species with Lactobacillus species, that did not report a significant decrease in 
the incidence of NEC was a double-blind, randomized clinical trial undertaken by Fernandez-
Carrocera et al., (2013). Although there was a decrease in NEC in the study group, 8% versus 
16%, the p-value was 0.132 and therefore these results, while clinically significant are not 
statistically significant (Fernandez-Carrocera et al., 2013). It has been shown through molecular 
studies that in the healthy gut of a breastfed infant Bifidobactrium species can represent 
anywhere between 60% and 90% of the total fecal microbiota. Therefore, these results can 
possibly be attributed to the use of 4 Lactobacillus strains and only 1 Bifidobactrium stain. This 
specific combination does not mimic the microbiota of a healthy infant (Lin et al., 2008).  
Population 
 The number of infants in the studies reviewed ranged from 150 to 434. Larger sample 
sizes carry more weight than small sample sizes, however small sample sizes are acceptable as 
when a power analysis is conducted to determine the minimal number of participants needed to 
produce valid results. A power analysis was done in all three studies to ensure the minimum 
participant number was met. However, in the Braga et al., (2011) trial, the research was 
discontinued after one year rather than continuing the originally planned 2-year period of time 
due to the trial producing clear benefits in the probiotic group. For this reason, Braga et al., 
(2011) did not met the minimum participant number of 282 in each group which weakens the 
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validity of their results. By comparison, both Lin et al., (2008) and Fernandez-Carrocera et al., 
(2013) met the minimum participant requirement.  
 Lin et al., (2008) was the only study of this entire literature review that categorizes its 
results based on birth weight. This helps to identify the true effects of probiotics on the extreme 
low birth weight infants (ELBW) which is any infant weighting less than 1000g at birth. 
Unfortunately, Lin et al., (2008) failed to stratify its participants based on birth weight during the 
randomization of its participants. This caused the study group to have a significantly lower 
average birth weight when compared to the control group (there were 33 infants weighting less 
than 750g in the study group and only 18 infants weighing less than 750g in the control group). 
This lower birth weight average in the study group puts the participants at a greater acuity and 
therefore increased risk of NEC than those infants in the control group. Despite this, there was 
still a significant reduction in the incidence of NEC.  
 Infants were excluded from all three trials if they had major congenital malformations 
such as congenital intestinal atresia or gastroschesis, previously diagnosed life-threatening 
chromosomal abnormalities, or severe asphyxia. Lin et al., (2008) included additional exclusion 
criteria such as exclusive formula feedings and infants who had been fasted for greater than 3 
weeks. Clinical similarities in all three trials made it easier to accurately compare acuity of the 
participants.  
 Inclusion criteria of <1500g birth weight and <32 gestational age at birth was consistent 
between the three trials however, the average birth weight and gestational age varied. Gestational 
age ranged from 29.3 weeks (Braga et al., 2011) to 31.1 weeks (Fernandez-Carrocera et al., 
2013). Lin et al., (2008) did not specify the average gestational age of the participants, they 
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simply stated that all infants were less than 32 weeks gestational age. Birth weight ranged from 
an average of 1,053g (Lin et al., 2008) to 1,173g (Braga et al., 2011).  
Specific Type and Strength of Probiotic 
  There were various forms and doses of Bifidobactrium and Lactobacillus administered in 
the studies reviewed. Fernandez-Carrocera et al., (2013) even added one strain of streptococcus 
into the probiotic mix. The only two probiotic types seen in two studies were L. acidophilus 
(Fernandez-Carrocera et al., 2013; Lin et al., 2008) and L. casei (Fernandez-Carrocera et al., 
2013; Braga et al., 2011). More over two of the three studies investigated the reduction of NEC 
using two strains of probiotic (Lin et al., 2008; Braga et al., 2011) while, Fernandez- Carrocera et 
al., 2013) employed the use of six various probiotics strains, four of which were Lactobacillus 
strains. The vast difference in type of probiotic studied makes it near impossible to identify 
which specific strain combination of Bifidobactrium and Lactobacillus create the greatest 
reduction in NEC incidence.  
 The dose presentation between the three studies also varies greatly. Although all three 
trials measure the probiotic by CFU’s the dosing was random and ranged from 3.5 x10^7 (Braga 
et al., 2011) to 1x10^9 (Lin et al., 2008; Fernandez-Carrocera et al., 2013) and everywhere in 
between. The only consistency in dosing was in Lin et al., (2008) and Fernandez-Carrocera et al., 
(2013) where 1x10^9 CFU’s of L. acidophilus are used. This inconsistency of dosage made it 
impossible to compare the doses of various probiotics.   
Timing of the Introduction, Duration of Administration and Feeding Regimes 
 The introduction time, length of administration and feeding regimes were different for 
each study. Probiotic supplementation was started when the first enteral feeds were started 
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(Fernandez-Carrocer et al., 2013; Lin et al., 2008) or on the second day of life (Braga et al., 
2011). Furthermore, the duration of administration ranged from 30 days (Braga et al., 2011) to 
until 6 weeks (Lin et al., 2008) to until discharge or death (Fernandez- Carrocera et al., 2013).  
 The feedings regimes were comparable between the three studies. Lin et al., 2008 and 
Braga et al., (2011) were both very detailed in the protocol for advancing feeds and neither study 
advanced feeds more than 20mL/kg per day. However, Braga et al., (2011) did not stop probiotic 
administration during times of feeding intolerance like Lin et al., (2008) and Fernandez-
Carrocera et al., (2013). All three studies allowed the use of human milk and/or fortified preterm 
formula for feeding however, Braga et al., (2011) specifically fed the infants breast milk until the 
third week of life and then introduced fortified preterm formula to their diet. This inconsistent 
milk forms between these studies makes it difficult to analyze the effects of probiotics.  
Lactobacillus Species  
 
 This literature review returned two articles that met the inclusion criteria, which focused 
on Lacrobacillus species as the single agent of investigation.  
Incidence of NEC 
 Both Sari et al. (2011) and Oncel et al. (2014) found that the use of lactobacillus species 
produced no significant effect on the incidence of necrotizing enterocolitis stage 2 or greater. 
Oncel et al., (2014) reported the rate of NEC amongst the probiotic group participants to be 4%. 
This is only slightly reduced from the control group which had a NEC rate of 5%. With a p-value 
of 0.63, this reduction in NEC cannot be considered statistically or clinically significant. These 
results mirror the findings in the Sari et al., (2011). Sari et al., (2011) reported a NEC incidence 
rate of 5.8% in the study group and 9% in the control group with a p-value of 0.447. Like the 
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Oncel et al., (2014) study these are not statistically significant results. Sari et al, (2011) attributes 
the lack of change in incidence of NEC to the small population size and the interference of 
intestinal blood flow caused by umbilical venous catheters that were in place significantly longer 
in the study group than the control group.   
Population 
 The researchers in both of the lactobacillus studies examined in this literature review 
excluded infants that were at an increased risk for NEC such as infants exposed to prenatal 
steroids, prolonged rupture of the amniotic membranes and asphyxia (Oncel et al., 2014; Sari et 
al., 2011). The demographic and clinical similarities between the participants of the two studies 
created an advantage for this review. Both research studies used event analysis with an α-error 
set at 0.05, the β-error set at 0.2 with an absolute reduction in incidence of NEC of 50%. Sari et 
al., (2011) determine that to verify the hypothesis the minimum number of participants needed in 
each arm of the study was 111 infants. There were 110 infants in the probiotic group and 111 
infants in the control group therefore, the minimum number of participants was not achieved for 
the probiotic group which reduces the validity of the results presented in this study. Oncel et al., 
(2014) determined that the minimum number of participants in each arm needed to be 190. This 
minimum was achieved with 200 infants in both the study and control group thereby 
strengthening the validity of results in this study.  
 The participants in the Oncel et al., (2014) were slightly younger with an average 
gestational age of 28.0 weeks versus 29.6 gestational weeks in the Sari et al., (2011) participants. 
Likewise, the participants in the Oncel et al., (2014) study were also smaller than the Sari et al, 
(2011) participants with an average birth weight of 1,059.5g versus 1,254.5g, respectively. This 
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near two week and 200g difference between the participants of the two studies makes it difficult 
to comparatively analyze the results.  
Specific Type and Strength of Probiotic 
The specific strains of probiotic investigated in the Oncel et al., (2014) study and the Sari 
et al., (2011) study differed from one another. Oncel et al., (2014) supplemented feedings with L. 
reuteri and Sari et. al, (2011) supplemented feedings with L. sporogens, which was the first 
study to examine L. sporogens. Unfortunately, there is a deficit in research examining the 
effectiveness of these two strains of Lactobacillus in reducing NEC. For this reason, it is 
impossible to say which of these two strains carries the greatest benefit. However, it is thought 
that the main action of all Lactobacillus species is to aid and regulate the host- defense 
mechanisms of the intestines. It is possible then, that all lactobacillus species will produce 
similar results, in regards to decreasing NEC, as these two studies but further research is needed 
to confirm the validity of this hypothesis.  
In terms of probiotic strength, the presentation of dose strength was the same which made 
it easy to decipher the equality of the strengths. Oncel et al., (2014) supplemented feedings with 
100,000,000 CFU and Sari et al., (2011) supplemented feedings with 350,000,000 CFU. The 
supplementation in the Sari et al., (2011) study is significantly larger which makes it peculiar 
that there was no significant reduction in NEC incidence. This study design would need to be 
repeated in further research to determine the variables attributing to the insignificant NEC 
reduction.  
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Timing of the Introduction, Duration of Administration and Feeding Regimes 
 Introduction time, administration duration and feedings regimes were comparable in both 
lactobacillus studies. Probiotics were introduced with the first feed and when the participants 
were clinically stable (Oncel et al., 2014; Sari et al., 2011). However, details as to the exact day 
of first feed was not reported. For all participants in both studies, probiotics were administered 
until discharge or death. Furthermore, both studies started the feeding at a rate of 10-20mL/kg 
per day and restricted the advancement of feeds to no more than 20mL/kg per day. Also for 
participants in both study designs, feedings were stopped if there were two or more signs of 
feeding intolerance and held until the feeding intolerance resolved (Oncel et al., 2014; Sari et al., 
2011).  
 The methodology differences between Oncel et al., (2014) and Sari et al., (2011) 
appeared in the mechanism of administration of probiotics. Oncel et al., (2014) administered the 
probiotic supplementation by placing 5 drops of L. reuteri in an oil based suspension on the back 
of the oropharynx of the infants while Sari et al., (2011) added the L. sporogenes to the milk 
feeds. There was no mention by Oncel et al., (2014) as to how this unique administration could 
have affected results nor has this study been repeated. For this reason, it is impossible to 
determine if the two administration methods cause variable results.  
Saccharomyces Species  
 
 Two studies investigating the use of Saccharomyces species met the inclusion criteria for 
this literature review.  
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Incidence of NEC 
 Neither the study by Demirel, Erdeve, Celik & Dilmen (2013) nor the study by Serce, 
Benzer, Gursoy, & Ovali (2013) reported any decrease in NEC in the infants studied. Demirel et 
al. (2013) was the first randomized, controlled trial to investigate the use of S. boulardii as a 
preventative method to NEC. This study reported the rate of NEC in the study group as 4.4% 
which is just slightly lower than the rate of 5.1% in the control group however, this was not a 
statistically significant decrease with a 95% confidence interval and p-value of 1 (Demirel et al., 
2013). Additionally, in both the study and the control group there were two cases of NEC stage 3 
(severe NEC).  
Population 
 The number of infants in the studies investigating Saccharomyces species were rather 
similar with 271 in the Demirel et al. (2013) study and 208 in the Serce et al. (2013) study. 
Through event rate analysis Serce et al. (2013) was able to determine that in order to verify their 
hypothesis they would need a minimum of 104 in the study group and 92 in the control group. 
With 104 in both the study and control group they met the minimum population size which 
strengthens the validity of the results presented in this study (Serce et al., 2013). Likewise, 
Demirel et al. (2013) determined through event analysis that the minimum population size for 
both the study and control arm was 111. This minimum population size was met with 135 in the 
study group and 136 in the control group therefore, the validity of the results reported is 
strengthened. Both Demirel et al. (2013) and Serce et al. (2013) used an α-error of 0.05 and a β-
error set at 0.2 with an absolute reduction in the incidence of NEC of 50%.  
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 In terms of average gestational age and weight of the participants, both the Demirel et al. 
(2013) and the Serce et al. (2013) studies were comparable with average gestational ages of 29.3 
weeks and 28.7 weeks respectively, and average weights of participants at 1,147.5g and 1,144g, 
respectively. Furthermore, the demographics between the study participants were similar with 
both research groups excluding infants with clinical signs that put them at an increased risk for 
NEC.  
Specific Type, Dose and Strength of Probiotic 
 Both Demirel et al. (2013) and Serce et al. (2013) investigated Saccharomyces boulardii. 
The difference between these two studies is in the dosage and strength of probiotic. Demirel et 
al. (2013) investigated S. boulardii at a strength of 250mg per day while Serce et al. (2013) 
investigated this probiotic strain at 50mg/kg/12 hour. Adjusting this to show comparisons this is 
100mg/kg per day. The average weight in kg between both the study and control group was 1.14 
kilograms (Serce et al., 2013). Therefore, the average dose of probiotic given to the infants in 
this study was roughly 114mg per day. Less than half the dosing given to the study participants 
in the study by Demirel et al. (2013).  
 The strength of S. boulardii used in these two studies was difficult to compare due to the 
differing presentation of the strengths. Demirel et al. (2013) reports using 5 billion colony 
forming units (CFU), while Serce et al. (2013) used a numerical value of 0.5 x 109 cell/kg/dose. 
This made it impossible to compare the strengths used in these two studies. 
Timing of the Introduction, Duration of Administration and Feeding Regimes 
 The timing of probiotic introduction was slightly different for these two studies. Both 
studies started probiotic supplementation at the time feedings commenced. However, Demiral et 
 27 
al. (2013) commenced feedings 48 hours after birth whereas Serce et al. (2013) commenced 
feedings at only 24 hours after birth. Although a 24-hour difference in the commencement of 
feedings does not appear to be clinically significant, in the life of a preterm infant, 24 hours is 
very clinically significant. Unfortunately, neither study comments as to why this particular 
initiation time was chosen and makes no mention about the participants being clinically stable at 
the time feedings commenced.  
 There were methodology similarities between Serce et al. (2013) and Demiral et al. 
(2013) in regards to the duration of administration and feeding regimes. Both studies continued 
probiotic supplementation until either discharge or death of the infant. Also, both studies began 
feeding each participant with 10-20mL/kg/day of either fortified formula or human breast milk. 
The variation between the studies appeared in the method of advancing feedings. Demiral et al. 
(2013) gave very scarce guidelines as to how the feedings were advanced, simply stating that the 
advancement of feeds did not exceed 20mL/kg/day. By comparison Serce et al. (2013) listed 
very systematic methods as to how the feedings were increased based upon the infant’s weight: 
10mL/kg/day for infants weighing <750g; 20mL/kg/day for infants weighing 750-1250g; and 
30mL/kg/day for infants weighing 1250-1500g. Furthermore, Serce et al. (2013) added a fortifier 
to the human milk once the goal feeding of 100mL/kg/day was achieved. Demiral et al. (2013) 
makes no mention of additional fortifiers added to feedings.  
 Although the differences between these two studies are not extreme, the use of both 
breast milk and fortified formula amongst the participants makes evaluating the benefits of 
probiotics difficult.  
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Other Considerations 
Rate of Sepsis 
Although the study performed by Oncel et al., (2014) investigating the use of L. reuteri 
showed no significant reduction in the rate of NEC there was a statistically significant reduction 
in the rate of sepsis between the study group and the control group. With a p-value of 0.041, the 
rate of sepsis in the study group was only 6.5% whereas in the control group there was 12.5% of 
participants with proven sepsis (Oncel et al., 2014). Comparatively, the rate of culture-proven 
sepsis in the Sari et al., (2011) study was not statistically lower in the study group (26.4%) when 
compared with the control group (23.4%) with a p-value of 0.613. It is difficult to determine the 
cause of the drastically different results in sepsis occurrence due to the many inconsistencies 
between the two studies including but not limited to the specific strain of Lactobacillus 
investigated. More importantly however, in both studies, none of the positive blood cultures 
grew Lactobacillus bacteria. Therefore, the risk of sepsis as it relates to Lactobacillus 
supplementation appears extremely low.   
 Despite the Demiral et al. (2013) study showing S. Boulardii at a dose of 250mg/day 
ineffective in preventing NEC, their study did report a statistically significant reduction in the 
rate of clinical sepsis. With a rate of 34.8% in the study group and 47.8% in the control group 
with a 95% confidence interval. However, more importantly is that none of the positive blood 
cultures grew S. Boulardii. By comparison, Serce et al. (2013) reported no significant difference 
in the rate of sepsis between the probiotic study group and the control group.  
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Rate of Feeding Intolerance 
 Similar results were also reported in both the Lactobacillus studies. A statistically 
significant reduction was observed in feeding intolerance for both the Oncel et al., (2014) and the 
Sari et al., (2011) studies were reported: 28% vs. 39.5% with a p-value of 0.015 and 44.5% vs 
63.1% with a p-value of 0.006, respectively.  
Similarly, to the rate of sepsis, Demiral et al. (2013) reported that S. Boulardii at a rate of 
250mg/day can provide a statistically significant decrease in feeding intolerance for premature 
infants. In the probiotic group, only 22.9% of the infants had at least one episode of feeding 
intolerance whereas 48.1% of the infants in the control group had at least one episode of feeding 
intolerance. By comparison, Serce et al. (2013) reported no significant difference in the rate of 
feeding intolerance or time to reach full enteral feedings between the study group and the control 
group.  
Duration of Hospitalization 
 
 Amongst the studies investigating Lactobacillus species, a significant difference in length 
of hospital stay was reported from the Oncel et al., (2014) study with the probiotic group 
participants having an average stay of 38 days and the control group participants staying an 
average of 46 days in the hospital with a p-value of 0.022. The second study investigating 
Lactobacillus, Sari et al., (2011), did not have any mention of hospital stay amongst its 
participants.   
The research studies investigating S. Boulardii by Serce et al. (2013) and Demiral et al. 
(2013) both reported that S. boulardii supplementation had no significant effect on the length of 
a neonate’s hospital stay.  
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Summary 
Table 1: Bifidobactrium combined with Lactobacillus Species 
Author Probiotic Used Dose Sample size Length of 
treatment 
Gestation 
at initiation 
of 
treatment 
Increase 
or 
decrease 
of NEC 
Incidence of 
NEC: Study 
vs. Control 
Braga 
et.al., 2011 
B. breve 
L. casei 
3.5 · 107 to 3.5· 
109 CFU;  
 
231 babies <1500g 
(119 probiotics and 
112 control) 
Once daily for 
30 days 
2 days post 
birth 
Decrease 0 in study group 
and 4 in control 
group.  
P .05 
Fernández-
Carrocera 
et. al, 2013  
 
B. breve 
B. bifidum 
B. infantis 
B. longum 
L. rhamnosus GG  
 
2 x 10^9 CFUs  
 
294 participants in the 
study group; 317 
participants in the 
control group  
Once daily 
until 34 weeks 
gestation. 
Starting 
with the 
first enteral 
feeding 
Decrease  Probiotic: 5.4% 
Placebo: 9.8% 
(P < .02)  
 
Janvier, A; 
Malo, J., & 
Barrington, 
K., 
2014Javier,  
L. acidophilus 
L. rhamnosus 
L. casei 
L. plantarum 
B. infantis 
Streptococcus 
thermophillus  
 
1g per day 
diluted in 3ml of 
milk  
 150 babies (75 and 
75) <1500g 
 Once daily. No 
other specifics 
noted. 
Starting 
with the 
first enteral 
feeing  
Decrease  6 (8%) versus 
12 (16%) in the 
control group 
but the 
difference was 
not statistically 
significant.  
(p=0.132)  
 
 Lin et. al., 
2008 
B. bifidum 
L. acidophilus   
10^9 CFU and 
10^9 CFU 
respectively 
@125mg/kg/dose  
434 babies <1500g 
<34 weeks  
Twice daily for 
6 weeks  
Starting 
with the 
first enteral 
feeding  
Decrease 
of NEC  
≥stage 2 
NEC/Death: 
P.002 
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Table 2: Lactobacillus used alone 
Author Probiotic 
Used 
Dose Sample Size Length of 
Treatment 
Gestation 
at 
initiation 
of 
treatment 
Increase or 
Decrease of 
NEC 
Incidence of NEC: 
Study vs Control 
Oncel 
et. al., 
2014 
L. reuteri 100 million CFU/day 
(5 drops) lyophilized  
 
400 babies 
with gestation 
≤32 weeks and 
birth weight 
≤1500g 
Daily until 
discharge 
Starting at 
first 
feeding 
No effect There was no 
statistically significant 
difference between 
groups in terms of 
frequency of NEC 
stage ≥2 (4% vs 5%; 
p=0.63) or overall 
NEC or mortality rates 
(10% vs 13.5%; 
p=0.27)  
 
Sari et. 
al, 
2011 
L. sporogenes 350 000 000 CFU 
1ml suspension was 
added to breast milk 
or formula 
 
221 babies 
with gestation 
of <33 weeks 
or birth weight 
of <1500g 
(110 in the 
study group 
and 111 in the 
control group)  
Daily Until 
discharge 
Once they 
could 
enterally 
feed and 
then 
starting at 
first 
feeding 
No effect The incidence of NEC 
was not significantly 
lower in the probiotics 
group than in the 
control group (5.8 vs 
9%, respectively; P 1⁄4 
0.447).  
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Table 3: Saccharomyces used alone 
Author Probiotic Used  Dose Sample Size Length of 
Treatment 
Time of 
initiation of 
treatment 
Increase or 
decrease of 
NEC 
Incidence of NEC: 
Study vs Control  
Demirel et. 
al., 2013 
S. boulardii 250 mg/ 
day of 5 
billion 
CFU 
 
217 babies with 
gestation ≤ 32 
weeks and birth 
weight  
≤1500g  (135 in the 
study group and 
136 in the control 
group) 
Once daily 
until 
discharge  
Once they 
could be 
enterally 
fed. Starting 
with first 
feed.  
No  
significant 
effect 
4.4% vs. 5.1%, 95% 
CI, !0.65–5.12; p = 
1.0)  
However, it did 
improve feeding 
intolerance and 
reduced risk for 
sepsis 
 
Serce et. 
al., 2013 
S. boulardii 50 mg/kg 
every 12 
h  
 
208 babies with 
gestation ≤32 and 
birth weight ≤1500 
g (104 in the study 
group and 104 in 
the control group) 
Every 12 
hours until 
discharge  
Once they 
could be 
enterally 
fed. Starting 
with the 
first feed  
No effect The incidence of 
stage ≥2 NEC was 7 
(6.7%) both in the 
control and study 
group, and it did not 
reach statistical 
significance (p = 1)  
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Discussion  
 Necrotizing enterocolitis remains one of the most devastating pathologic processes faced 
by premature infants with an unchanging incidence rate of 7%-14% and significant mortality of 
up to 30% (Deshpande et al., 2010). It is known that the pathogenesis of NEC involves a series 
of factors, with prematurity (less than 37 weeks gestation) consistently documented as one of the 
most influential (Braga et. al, 2011; Lin et. al, 2008). Aside from the high incidence and 
mortality rate associated with NEC, there is also an increased need for surgery to remove the 
areas of necrotic bowel and long-term ramifications, such as short bowel syndrome and its 
associated consequences of recurrent sepsis and total parenteral nutrition (TPN) dependence 
(Deshpande et al., 2010). It has been documented that surgically treated NEC, typically seen in 
Stage 3 or “advanced NEC” can prolong neonates’ hospital stay up to 60 days and cause long-
term neurodevelopmental impairment (NDI) (Deshpande et al., 2010; Schulzle S.M., Desphande 
G.C., & Patole SK, 2007). NDI encompasses cerebral palsy, bilateral blindness or bilateral 
deafness (Reese, C.M., Pierro, A., & Eaton, S., 2007).  In the study by Schulzle et al. (2007) it 
was found that neonates with definite NEC (Bells stage 2 or greater) were significantly more at 
risk for long-term NDI when compared to infants who did not develop NEC with an odds ratio of 
1.82. Factors causing NDI in premature infants are complex. Brain development continues into 
the second and third trimester. Therefore, infants born premature have a deficit in neuronal 
maturation which increases the risk for long-term NDI (Reese, C.M. et al., 2007). Proper 
nutrition is essential for the continued growth of the brain after birth. Nutrition becomes 
problematic for the infants with NEC considering NEC is associated with increased rates of 
feeding intolerance (Janvier, 2014). The issue of nutrition is furthered in the infant whose NEC is 
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treated surgically. When sections of gangrenous bowel are removed surgically due to NEC the 
infant has smaller gastrointestinal surface area to absorb necessary nutrients (Reese, C.M. et al., 
2007). This is known as short bowel syndrome.  
The microbiota within the gastrointestinal system must remain balanced between healthy 
gut bacteria, such as Bifidobactrium and Lactobacillus, and pathologic bacteria, such as 
staphlococcci, enterobacter, enterococci, and clostridia. If this balance is disturbed, for example 
by an over proliferation of pathologic bacteria, disease such as NEC can occur (Lin et al., 2008).  
It has been hypothesized that preterm infants fed probiotic supplements containing 
bacteria found within the healthy newborn gut would have a decreased incidence of NEC (Braga 
et al., 2011; Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008) . There is strong 
evidence supporting the benefits of prophylactic use of probiotics but more research is necessary 
to support the practice of routine probiotic supplementation. Among the literature reviewed there 
was a lack of consistency in study design (probiotic strain, dosage, feeding protocol, and 
duration) and this has led to debate about the effectiveness of probiotics in preventing NEC as 
some studies (Demirel et. al., 2013; Serce et. al., 2013) show no reduction in NEC, while others 
report astounding reduction (Braga et. al., 2011; Javier et al., 2014; Lin et. al., 2008). 
Inconsistency in feeding protocol, human milk versus formula, may be attributed to reports, such 
as by Guaraldi, F. & Salvatori, G. (2012), stating that the type of milk fed does not significantly 
alter the gut ecosystem, and therefore causing researchers to believe the type of milk does not 
alter results.   
The strains investigated in this literature review included Bifidobactrium strains 
combined with lactobacillus strains, lactobacillus strains used alone and Saccharomyces strains 
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used alone. These three categories of probiotic species were investigated because they were the 
most frequently studied among current research (Deshpande et al., 2010). Despite the narrowed 
categories and the exclusionary criteria used in this review, a total of 12 different strains are 
represented between the studies. While there is some overlap in probiotic strains, little 
similarities in the duration of administration/administration parameter, time of initiation, or 
combination of strains was found. It is important to note that the mechanism of action of 
probiotics is strain specific (Serce et al., 2013). With no two studies matching in probiotic strains 
investigated a significant limitation was placed on the ability to compare studies in this review.  
Bifidobactrium combined with Lactobacillus  
 
 It is well known among health professionals versed in the intestinal health of infants that 
the healthy newborn’s intestines are colonized primarily by species of Bifidobactrium bacterial 
species. In fact, molecular studies show that 60%-90% of gut colonization in a healthy newborn 
is by Bifidobactrium species specifically, Bifidobactrium bifidum, Bifidobactrium longum and 
Bifidobactrium breve (Lin et al., 2008). The knowledge of this provides a clear rationale as to 
why the studies using a combination of Bifidobactrium and Lactobacillus strains (Braga et al., 
2011; Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008) are reporting a reduction 
in NEC among their study participants. All but one (Fernandez-Carrocera et al., 2013) of the 
research studies using the combination of Bifidobactrium and Lactobacillus found that there was 
a statistically significant decline in the incidence of NEC when these species of probiotics were 
added to feedings. More specifically, B. breve appears to be the most frequently studied 
Bifidobacrium strain studied due to its high affinity with the immature intestine and its large 
presence in the gut of a healthy newborn (Deshpande et al., 2010).  
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 Among the studies investigating Bifidobactrium and Lactobacillus, (Braga et al., 2011; 
Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008) three of the four studies 
reported a statistically significant reduction in NEC. This suggests that the use of probiotics, 
specifically Bifidobactrium and Lactobacillus may prevent the occurrence of NEC stage 2 and 
greater. The American Academy of Pediatrics (Section on Breastfeeding, 2012) recommends 
exclusively feeding preterm infants human breast milk, citing that one of the benefits is the 
reduced incidence of NEC. While human milk contains oligosaccharides that are beneficial to the 
neonatal gastrointestinal system, and has even shown to reduce NEC (Lin et al., 2008), feeding 
human milk alone cannot completely eradicate the incidence of NEC (Deshpande et al., 2010). 
This is attributed to interleukin 10 deficiency in preterm newborns. As previously mentioned, 
Bifidobactrium species and Lactobacillus species have both been shown to induce interleukin 10 
production (Lin et al., 2008). Therefore, probiotics and human milk may work synergistically to 
reduce the incidence of NEC (Lin et al, 2008). This hypothesis would need to be studied further 
due to a scarcity of research investigating the use of probiotics in conjunction with exclusively 
human milk fed preterm infants.  
Despite the promising results with Bifidobactrium and Lactobacillus, the number of 
studies that have evaluated the association of these two probiotics remains extremely low (Braga 
et al., 2011) and not a single study design has been repeated. As a result, health professionals are 
hesitant to implement probiotic supplementation into standard practice (Braga et al., 2011).  
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Lactobacillus Species Used Alone and Saccharromyces Species Used Alone 
 
 As previously stated, this literature review supports prior meta-analyses in showing that 
when only one species of probiotic is used alone, there is no reduction in the incidence of NEC 
(Deshpande et al., 2010). The studies that investigated Lactobacillus species or Sacharromyces 
showed no significant reduction to NEC. It should be pointed out that Saccharromyces is actually 
a yeast rather than a bacterium. Still considered a probiotic, yeast such as Saccharromyces 
species have been shown to antagonize both other yeasts and bacteria in a similar fashion as 
bacterial probiotics (Serce et al., 2013). Despite animal studies showing the potential for 
Saccharromyces species to inhibit pro-inflammatory mediator release, there was no reduction of 
NEC seen in this review (Serce et al., 2013). These results may be attributed to a differing 
immune response by the gut mucosal cells due to the substantial difference in cell wall structure 
between yeast and bacteria (Serce et al., 2013). This however, is just a hypothesis and further 
studies investigating the use of yeast would need to be conducted.  These two probiotic species 
cannot be completely dismissed however. Both Lactobacillus and Saccharomyces studies 
showed that there was a significant reduction in the rate of feeding intolerance (Demirel et al., 
2013; Oncel et al., 2014; Sari et al., 2013). For improved overall prognosis of this high-risk 
population, it is essential to establish optimal enteral nutrition as early as possible in the postnatal 
life (Deshpande et al., 2010). For this reason, supplementing feedings with these two species of 
probiotics would not be futile if its purpose was to enhance enteral nutrition via improved gastric 
emptying, and gut barrier function (Deshpande et al., 2010).  
 Results in terms of sepsis reduction and overall hospital stay were sporadic between the 
Lactobacillus and Saccharomyces studies and therefore it is inconclusive whether these species 
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can produce a significant reduction in these two events. The variation in results could be 
attributed to the heterogeneity in study designs (Deshpande et al., 2010). The inconsistent 
reduction in sepsis incidence seen in this review may also be attributed to the multiple sources of 
entry for various pathogens such as endotracheal tubes, central venous catheters, lipid infusions 
and TPN (Deshpande et al., 2010). Therefore, probiotics may have the ability to reduce the 
presence of coagulase-negative Staphylococcus (CONS), which is primarily found in the gut, but 
it it less likely that probiotics could overcome the burden of pathogens from these other entry 
points (Deshpande et al., 2010). It is reassuring however, that there were zero sepsis related 
deaths and zero probiotic related sepsis occurrences in this literature review (Braga et al., 2011; 
Demireal et al., 2013; Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008; Oncel et 
al., 2014; Sari et al., 2011; Serce et al., 2013)  
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Conclusion  
 Necrotizing Enterocolitis is a severe life threatening gastrointestinal disease that often 
leads to death for premature neonates. In order to reduce the mortality rate associated with this 
disease it is vital to determine an effective preventative strategy . There is currently insufficient 
knowledge regarding the precise etiology, disease process, or the long-term consequences of 
NEC to prescribe a definitive preventative method. For this reason, research into the preventative 
use of probiotics, among other  interventions such as, mothers own milk, increased oxygenation, 
prebiotics and steroids is ongoing. Furthermore, the use of probiotics as a preventative treatment 
for NEC has not been thoroughly researched in the extremely premature infant population (<28 
weeks gestation). Therefore, although the results are promising further research is needed before 
the use of probiotics can be determined a safe prophylactic treatment for the generalized 
premature population.  
 The consensus between all studies investigating the use of probiotics is that it is an 
attempt to mimic the natural bowel colonization and microbiota of a healthy infant born full term 
(Deshpande et al., 2010). Although the use of probiotics appears promising, it should be 
highlighted that all of the studies included in this literature review reported NEC when it was 
confirmed at stage 2 or greater according to Bell’s Criteria. This omits the early stages of NEC, 
or “suspected NEC”. There is little to no research related to probiotics and their ability to prevent 
NEC development in these early stages. While NEC stage 2 and greater is associated with the 
greatest risk for mortality, NEC stage 1 still has the ability to cause morbid conditions with life-
long health consequences such as a distended abdomen (Braga et. al, 2011). It is possible that if 
the confirmed outcome was expanded from “Confirmed NEC stage 2 or greater” to simply 
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“NEC, including suspected NEC”, the effects of probiotics in reducing NEC incidence would be 
less significant. 
 Considering the results vary among the species specific research designs it is impossible 
to determine if there is a precise strain of probiotic more suitable to prevent NEC in the preterm 
infant. Despite the variable results and large variety of probiotic strains, this literature review 
further supports prior meta-analysis such as Deshpande et. al. (2010) that conclude that the 
administration of only one probiotic strain (eg. only one Lactobacillus strain or one 
Saccharomyces strain) is ineffective in reducing the incidence of NEC. By comparison, studies 
investigating the use of two or more strains of probiotics used in conjunction saw a significantly 
reduced incidence in the disease (Braga et al., 2011; Lin et al., 2008)  
 However, in conclusion, the great majority of research studies show a promising 
correlation between the combined use of Bifidobactrium species with Lactobacillus species and a 
decreased incidence in NEC for neonates born premature (Desphande et al., 2010).   
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Recommendations for Current Practice  
 
Due to the financial costs and deadly nature of NEC in premature neonates it is 
recommended that health care professionals discuss the potential benefits of probiotics with 
caregivers. As seen in this literature review, the risk for sepsis as a result of probiotics is 
extremely rare. There is also the added benefit of increased nutrition due to the reduced rate of 
feeding intolerance seen in infants given probiotics. Therefore, probiotics used as a prophylactic 
treatment for NEC comes with little risk other than cost of the probiotic itself which, in 
comparison to the cost of NEC treatment, is minimal (Janvier et al., 2014).  To ensure that this 
discussion occurs routinely it may be beneficial to provide an informational handout to parents or 
caregivers of premature neonates. This informational handout could educate parents on what 
NEC is and why their preterm newborn is at an increased risk of developing NEC. This would 
include how their preterm infant’s gut microbiota differs from that of a term newborn. The 
informational handout would also need to include the purpose of probiotics, which is to 
introduce “good” bacteria that mimics the bacteria seen in term newborns, and how the 
supplementation of probiotics might prevent the occurrence of NEC. It would have to be stressed 
however, that research is yet to be definitive on the most beneficial strain, dosage or 
supplementation method. That there is simply a strong correlation between probiotic 
supplementation and a reduction in NEC incidence. Therefore, health care professionals could 
not guarantee the prevention of NEC while discussing this preventative approach.   
In addition to suggesting the use of probiotics there are other preventative measures that 
that can incorporated in the NICU setting. This includes the continued use of antenatal 
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corticosteroids and exogenous surfactant to aid in lung develop which subsequently increases 
oxygenation of organs including the gastrointestinal tract. 
Finally, it would be beneficial that, when possible, strict feeding protocols of human milk 
feeds only be implemented in current practice.  This implementation can be accomplished by 
supporting mothers who choose to breast feed if their infant is able. This also includes supporting 
the mother during the time when a baby cannot adequately breast feed, by supporting the use of 
the breast pump and milk storage.  Human breast milk differs from formula milk in the nutrient 
composition but more importantly human milk contains growth factors, not found in formula, 
that aid in the maturation of a newborn’s gut epithelial cells and subsequent peristalsis and 
immunologic defenses necessary to maintaining a healthy gut ecosystem (Guaraldi F. & 
Salvatori G., 2012).  
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Recommendations for Future Practice 
 
As research continues to be conducted pointing towards the benefits of Bifidobacterium 
species and Lactobacillus species for NEC prevention, it is recommended that health care 
professionals begin using these probiotic strains as supplementation routinely on all neonates 
born before the 37th week of gestation or born weighing less than 1500g. It may be interesting to 
note that since Japan has introduced the routine use of probiotics to prophylactically treat NEC, 
their NEC incidence rate has decreased to approximately 1% (Taylor, R. S., 2014).  
Probiotic supplemented feedings would slightly increase the cost of routine care. 
However, the objective is to reduce the long term treatment costs associated with NEC and 
subsequently decrease the length of hospitalization for NICU patients. If incidence of NEC is 
reduced, the length of hospitalizations, cost of treatment for NEC and overall health of the 
neonate can improve. Current research shows that supplementing feedings with these probiotic 
strains produce a negligible risk for sepsis, and therefore has a beneficial risk-benefit balance 
(Taylor, R.S. 2014). The reality of the situation is that the gastrointestinal tracts of preterm 
infants are going to become colonized. Therefore, it becomes a matter of what type of bacteria 
that will colonize the GI tracts. The risk of an extremely rare case of sepsis occurring associated 
with the administration of probiotics, which is easily resolved via antibiotics (Janvier et al., 
2014), should be weighed against the significantly larger risk accrued when an infant’s GI tract is 
colonized by pathologic bacteria (Janvier et al., 2014).   
Additionally, there is a strong correlation with improved feeding tolerance and the use of 
probiotic supplemented feedings (Braga et al., 2011; Demiral et al., 2013; Oncel et al., 2014; Sari 
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et al., 2011) along with a reduced hospital stay (Oncel et al., 2014). Therefore, the benefits 
outweigh the cost.  
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Recommendations for Future Research 
 
 This review has identified several probiotic strains researched to reduce the incidence of 
NEC. It has also identified that the current research has vast inconsistences in methodology. 
Even among research studies that look at similar probiotic strands, the other independent 
variables such as number of colony forming units, time of initiation, and length of treatment vary 
so significantly that there is not a single repeated study design. This hinders the growth of 
knowledge on how to prevent NEC in NICU patients.  
 Therefore, it is important that going forward in the research of NEC prevention that study 
designs shown to be successful, such as the study by Lin et. al in 2008, are repeated to validate 
the effectiveness of these researcher’s methodology and validate the results. Only once variances 
between independent variables are reduced will HCPs have a basis for how to move forward in 
practice and prevention of this deadly disease process.  
 Due to the long-term consequences of NEC, such as short bowel syndrome, NDI, and 
frequent sepsis, research investigating the long-term ramifications of NEC, specifically in these 
areas, would greatly improve the overall knowledge of the pathogenesis of NEC. Additionally, as 
the ability to care for preterm infants increases it would be wise to look into the effects of 
prophylactic probiotic supplementation on extremely preterm infants (less than 28 weeks old).  
 Further research should also evaluate the effectiveness of incorporating additional 
prevention strategies such as improving oxygenation and tissue perfusion, strict feeding 
protocols that establish the use of human breast milk only, and slow advancements of enteral 
feeds.   
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Limitations  
 
As previously mentioned, the relationship between the incidence of NEC and prematurity 
is inversely related (Gephart et al., 2012). The typical neonate in a level III NICU is of high 
acuity, often times extremely premature at less than 32 weeks gestation, presenting with 
comorbidities, and significant genetic anomalies (Levels of Neonatal Care, 2004). The 
participants in this literature review were all less than 32 weeks gestation however, the 
exclusionary criteria was such that infants with genetic anomalies or gastrointestinal 
comorbidities were excluded. Therefore, it can be concluded that this literature review contains 
studies that did not always look at infants with the greatest risk for NEC. This is a limitation 
because it is not applicable to the extremely premature infant with confounding morbidities and 
therefore not generalizable to all NICU patients (Rohan & Wainwright, 2014).  
Another limitation to this literature review was that the scarcity of research made it so 
that no two studies were identical in probiotic strain, dosage or method of administration. It is 
important to note that the mechanism of action of probiotics is strain specific (Serce et al., 2013). 
Without repetition of probiotic strains investigated it is near impossible to determine with any 
certainty a single strain or combination of strains that is most effective in preventing NEC. 
Therefore, no definitive conclusion could be drawn as to which probiotic strain, dosage or 
method was most beneficial.   
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